FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313232803> ?p ?o ?g. }

• W4313232803 endingPage "245" @default.
• W4313232803 startingPage "245" @default.
• W4313232803 abstract "Introduction: Patients suffering from neurologic injuries with elevated intracranial pressure (ICP) often require pharmacologic management with mannitol or hypertonic sodium chloride. Hypertonic sodium chloride can lead to hyperchloremia, which is associated with increased risk of acute kidney injury and mortality. Alternative treatment strategies are therefore needed; one approach is to transition to hypertonic sodium acetate when patients develop hyperchloremia. Currently, there is a paucity of literature exploring hypertonic sodium acetate for ICP management. The objectives of this study are to describe the safety and effectiveness of hypertonic sodium acetate for ICP management. Methods: This is a retrospective cohort study of patients admitted to Mayo Clinic between 1/1/2010-12/9/2020. Patients who received at least two doses of hypertonic sodium acetate for management of elevated ICP were included. Baseline demographics were collected, and the safety of hypertonic sodium acetate was evaluated by changes in arterial pH, chloride, sodium, and renal function. The effectiveness of sodium acetate was assessed by ICP measurements. Results: Seventeen patients met the inclusion criteria. The median age was 55 years (IQR 47-61), and 59% were male. The most common diagnoses were acute ischemic stroke (29%), intracranial hemorrhage (29%) and traumatic brain injury (29%). The most common dose of sodium acetate was 75ml of 10%, and the median number of doses received was 9. Prior to initiating sodium acetate, the median sodium was 148 mEq (144, 150), median chloride was 113 mmol/L (111, 117), median pH 7.4 (7.4, 7.5), and median creatinine 1.0 mg/dL (0.7, 1.2). Twenty-four hours after transitioning to sodium acetate, the median sodium was 150 mEQ (148, 154) (median Δ 2), median chloride was 112 mmol/L (108, 117) (median Δ -3), median pH 7.5 (7.5, 7.5) (median Δ 0.1), and median creatinine 0.8 mg/dL (0.6, 1.3) (median Δ 0). The median ICP prior to sodium acetate initiation was 12 mmHg (4, 18), and the median ICP 24 hours after sodium acetate initiation was 9 mmHg (IQR 3, 11) (median Δ -3). Conclusions: Our findings suggest that transitioning to hypertonic sodium acetate for ICP management in patients experiencing hyperchloremia from hypertonic sodium chloride may represent a safe and effective alternative." @default.
• W4313232803 created "2023-01-06" @default.
• W4313232803 creator A5002637096 @default.
• W4313232803 creator A5017154876 @default.
• W4313232803 creator A5028767002 @default.
• W4313232803 creator A5029488636 @default.
• W4313232803 creator A5031713672 @default.
• W4313232803 creator A5053957832 @default.
• W4313232803 creator A5054056429 @default.
• W4313232803 creator A5078898801 @default.
• W4313232803 date "2022-12-15" @default.
• W4313232803 modified "2023-10-16" @default.
• W4313232803 title "515: SAFETY AND EFFECTIVENESS OF SODIUM ACETATE FOR INTRACRANIAL PRESSURE MANAGEMENT" @default.
• W4313232803 doi "https://doi.org/10.1097/01.ccm.0000907788.49390.36" @default.
• W4313232803 hasPublicationYear "2022" @default.
• W4313232803 type Work @default.
• W4313232803 citedByCount "0" @default.
• W4313232803 crossrefType "journal-article" @default.
• W4313232803 hasAuthorship W4313232803A5002637096 @default.
• W4313232803 hasAuthorship W4313232803A5017154876 @default.
• W4313232803 hasAuthorship W4313232803A5028767002 @default.
• W4313232803 hasAuthorship W4313232803A5029488636 @default.
• W4313232803 hasAuthorship W4313232803A5031713672 @default.
• W4313232803 hasAuthorship W4313232803A5053957832 @default.
• W4313232803 hasAuthorship W4313232803A5054056429 @default.
• W4313232803 hasAuthorship W4313232803A5078898801 @default.
• W4313232803 hasBestOaLocation W43132328031 @default.
• W4313232803 hasConcept C178790620 @default.
• W4313232803 hasConcept C185592680 @default.
• W4313232803 hasConcept C2777261373 @default.
• W4313232803 hasConcept C2778864100 @default.
• W4313232803 hasConcept C2779246250 @default.
• W4313232803 hasConcept C2780954326 @default.
• W4313232803 hasConcept C3017567848 @default.
• W4313232803 hasConcept C42219234 @default.
• W4313232803 hasConcept C537181965 @default.
• W4313232803 hasConcept C71924100 @default.
• W4313232803 hasConceptScore W4313232803C178790620 @default.
• W4313232803 hasConceptScore W4313232803C185592680 @default.
• W4313232803 hasConceptScore W4313232803C2777261373 @default.
• W4313232803 hasConceptScore W4313232803C2778864100 @default.
• W4313232803 hasConceptScore W4313232803C2779246250 @default.
• W4313232803 hasConceptScore W4313232803C2780954326 @default.
• W4313232803 hasConceptScore W4313232803C3017567848 @default.
• W4313232803 hasConceptScore W4313232803C42219234 @default.
• W4313232803 hasConceptScore W4313232803C537181965 @default.
• W4313232803 hasConceptScore W4313232803C71924100 @default.
• W4313232803 hasIssue "1" @default.
• W4313232803 hasLocation W43132328031 @default.
• W4313232803 hasLocation W43132328032 @default.
• W4313232803 hasOpenAccess W4313232803 @default.
• W4313232803 hasPrimaryLocation W43132328031 @default.
• W4313232803 hasRelatedWork W2079380504 @default.
• W4313232803 hasRelatedWork W2088421181 @default.
• W4313232803 hasRelatedWork W2095377791 @default.
• W4313232803 hasRelatedWork W2117661188 @default.
• W4313232803 hasRelatedWork W2272557906 @default.
• W4313232803 hasRelatedWork W2384903134 @default.
• W4313232803 hasRelatedWork W2396634796 @default.
• W4313232803 hasRelatedWork W2588111271 @default.
• W4313232803 hasRelatedWork W3112486730 @default.
• W4313232803 hasRelatedWork W3116673940 @default.
• W4313232803 hasVolume "51" @default.
• W4313232803 isParatext "false" @default.
• W4313232803 isRetracted "false" @default.
• W4313232803 workType "article" @default.